Tags

Type your tag names separated by a space and hit enter

Isofurans, but not F2-isoprostanes, are increased in the substantia nigra of patients with Parkinson's disease and with dementia with Lewy body disease.
J Neurochem 2003; 85(3):645-50JN

Abstract

F2-isoprostanes (F2-IsoPs) are well-established sensitive and specific markers of oxidative stress in vivo. Isofurans (IsoFs) are also products of lipid peroxidation, but in contrast to F2-IsoPs, their formation is favored when oxygen tension is increased in vitro or in vivo. Mitochondrial dysfunction in Parkinson's disease (PD) may not only lead to oxidative damage to brain tissue but also potentially result in increased intracellular oxygen tension, thereby influencing relative concentrations of F2-IsoPs and IsoFs. In this study, we attempted to compare the levels of F2-IsoPs and IsoFs esterified in phospholipids in the substantia nigra (SN) from patients with PD to those of age-matched controls as well as patients with other neurodegenerative diseases, including dementia with Lewy body disease (DLB), multiple system atrophy (MSA), and Alzheimer's disease (AD). The results demonstrated that IsoFs but not F2-IsoPs in the SN of patients with PD and DLB were significantly higher than those of controls. Levels of IsoFs and F2-IsoPs in the SN of patients with MSA and AD were indistinguishable from those of age-matched controls. This preferential increase in IsoFs in the SN of patients with PD or DLB not only indicates a unique mode of oxidant injury in these two diseases but also suggests different underlying mechanisms of dopaminergic neurodegeneration in PD and DLB from those of MSA.

Authors+Show Affiliations

Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

12694390

Citation

Fessel, Joshua P., et al. "Isofurans, but Not F2-isoprostanes, Are Increased in the Substantia Nigra of Patients With Parkinson's Disease and With Dementia With Lewy Body Disease." Journal of Neurochemistry, vol. 85, no. 3, 2003, pp. 645-50.
Fessel JP, Hulette C, Powell S, et al. Isofurans, but not F2-isoprostanes, are increased in the substantia nigra of patients with Parkinson's disease and with dementia with Lewy body disease. J Neurochem. 2003;85(3):645-50.
Fessel, J. P., Hulette, C., Powell, S., Roberts, L. J., & Zhang, J. (2003). Isofurans, but not F2-isoprostanes, are increased in the substantia nigra of patients with Parkinson's disease and with dementia with Lewy body disease. Journal of Neurochemistry, 85(3), pp. 645-50.
Fessel JP, et al. Isofurans, but Not F2-isoprostanes, Are Increased in the Substantia Nigra of Patients With Parkinson's Disease and With Dementia With Lewy Body Disease. J Neurochem. 2003;85(3):645-50. PubMed PMID: 12694390.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Isofurans, but not F2-isoprostanes, are increased in the substantia nigra of patients with Parkinson's disease and with dementia with Lewy body disease. AU - Fessel,Joshua P, AU - Hulette,Christine, AU - Powell,Suzanne, AU - Roberts,L Jackson,2nd AU - Zhang,Jing, PY - 2003/4/16/pubmed PY - 2003/6/18/medline PY - 2003/4/16/entrez SP - 645 EP - 50 JF - Journal of neurochemistry JO - J. Neurochem. VL - 85 IS - 3 N2 - F2-isoprostanes (F2-IsoPs) are well-established sensitive and specific markers of oxidative stress in vivo. Isofurans (IsoFs) are also products of lipid peroxidation, but in contrast to F2-IsoPs, their formation is favored when oxygen tension is increased in vitro or in vivo. Mitochondrial dysfunction in Parkinson's disease (PD) may not only lead to oxidative damage to brain tissue but also potentially result in increased intracellular oxygen tension, thereby influencing relative concentrations of F2-IsoPs and IsoFs. In this study, we attempted to compare the levels of F2-IsoPs and IsoFs esterified in phospholipids in the substantia nigra (SN) from patients with PD to those of age-matched controls as well as patients with other neurodegenerative diseases, including dementia with Lewy body disease (DLB), multiple system atrophy (MSA), and Alzheimer's disease (AD). The results demonstrated that IsoFs but not F2-IsoPs in the SN of patients with PD and DLB were significantly higher than those of controls. Levels of IsoFs and F2-IsoPs in the SN of patients with MSA and AD were indistinguishable from those of age-matched controls. This preferential increase in IsoFs in the SN of patients with PD or DLB not only indicates a unique mode of oxidant injury in these two diseases but also suggests different underlying mechanisms of dopaminergic neurodegeneration in PD and DLB from those of MSA. SN - 0022-3042 UR - https://www.unboundmedicine.com/medline/citation/12694390/Isofurans_but_not_F2_isoprostanes_are_increased_in_the_substantia_nigra_of_patients_with_Parkinson's_disease_and_with_dementia_with_Lewy_body_disease_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0022-3042&date=2003&volume=85&issue=3&spage=645 DB - PRIME DP - Unbound Medicine ER -